在患有SARS-CoV-2感染的年轻发烧婴儿中,细菌共感染
Susanna Hernández-Bou1,2, Victoria Trenchs3,4,5, Patricia Diego1
1Pediatric Emergency Department, Hospital Sant Joan de Déu, Passeig Sant Joan de Déu 2, 08940, Esplugues de Llobregat, Barcelona, Spain.
European journal of pediatrics
|October 23, 2023
概括
与未感染的婴儿相比,患有SARS-CoV-2感染的90天以下发烧的婴儿患严重细菌感染 (SBI) 的风险较低. 然而,在SARS-CoV-2阳性婴儿中,尿路感染仍然很常见.
科学领域:
- 儿科 儿科 儿科
- 传染性疾病 传染性疾病
- 病毒学 病毒学
背景情况:
- 90天以下发烧的婴儿有严重细菌感染 (SBI) 的风险.
- 关于SARS-CoV-2 (COVID-19) 对非常年幼婴儿SBI的影响的数据有限.
- 病毒感染通常与SBI风险降低有关.
研究的目的:
- 为了比较SBI在发烧的婴儿90天以下与或没有SARS-CoV-2感染的SBI的患病率.
- 为了确定这种人群中侵入性细菌感染 (IBIs) 的风险.
- 分析SARS-CoV-2对SBI发病率的影响,按年龄分层.
主要方法:
- 对779名发烧婴儿 (<90天) 进行了对SARS-CoV-2进行测试的回顾性队列研究.
- 纳入标准:发烧的婴儿<90天接受SARS-CoV-2检测.
- SBIs被定义为尿路感染,细菌病和/或细菌性脑膜炎;IBIs包括细菌病和脑膜炎.
主要成果:
- 在SARS-CoV-2阳性婴儿 (5.9%) 和阴性婴儿 (22.9%) 中,SBI的发生率明显较低.
- 尿路感染 (UTI) 是两组中最常见的SBI,但在SARS-CoV-2阳性婴儿中较少发生 (5.4%vs22.0%).
- 侵袭性细菌感染 (IBI) 率在SARS-CoV-2阳性婴儿中为0.5%,而在阴性婴儿中为3.2%;在SARS-CoV-2阳性婴儿中没有观察到细菌脑膜炎病例.
结论:
- 与SARS-CoV-2阴性婴儿相比,患有SARS-CoV-2感染的90天以下发烧的婴儿SBI的风险明显较低.
- 尽管整体风险较低,但在SARS-CoV-2阳性婴儿中,尿道感染仍然是一个相当大的问题.
- SARS-CoV-2 检测可能有助于评估29-89天的看起来良好的发烧婴儿的IBI风险.
相关概念视频
Pneumonia III: Complications and Assessment
242
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
242
Pneumonia II: Pathophysiology
296
The pathophysiology of pneumonia involves the following steps:
296
Pulmonary Tuberculosis IV
145
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
145
Pneumonia IV: Management
338
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
338
Factors Affecting the Risk of Infection
11.9K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
11.9K
Acute Respiratory Failure-II
249
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
249


